Psyence Biomedical Ltd., a vertically integrated biopharmaceutical company specializing in psychedelic-based therapeutics, provided a business update in its latest Management’s Discussion and Analysis. The company highlighted its position as the first life sciences biotechnology company focused on developing nature-derived psilocybin and ibogaine-based medicines to be listed on Nasdaq. Psyence Biomedical remains dedicated to addressing unmet mental health needs, particularly in palliative care, and continues to advance its evidence-based approach for the development of safe psychedelic medicines. The full report can be accessed through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Psyence Biomedical Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-002516), on January 08, 2026, and is solely responsible for the information contained therein.